A recent study reports that monocytes from patients with myeloproliferative neoplasms (MPNs) have a defective negative regulation of Toll-like receptor (TLR) signaling that allows for the unrestrained production of tumor necrosis factor alpha after TLR activation. Additionally, the authors write that TLR signaling not only contributes to chronic inflammation in patients with MPN, but also may predispose individuals to acquire MPNs.
Patients who have myeloproliferative neoplasms (MPNs) have high levels of inflammatory cytokines. A recent study, published in Blood Advances, reports that monocytes from patients with MPNs have a defective negative regulation of Toll-like receptor (TLR) signaling that allows for the unrestrained production of tumor necrosis factor alpha (TNF) after TLR activation. Additionally, the authors write that TLR signaling not only contributes to chronic inflammation in patients with MPN, but also may predispose individuals to acquire MPNs.
TNF is produced by monocytes when TLRs are stimulated, and negative feedback TLR signaling is needed to avoid overproduction of TNF. The authors of the study sought to understand whether TLR signaling is exaggerated in patients with MPN.
The investigators obtained peripheral blood from patients with polycythemia vera (PV), essential thrombocythemia, or myelofibrosis, as well as from their family members and from healthy volunteers who served as controls. They then measured TNF production by cluster of differentiation (CD) 14-positive monocytes stimulated with TLR agonists, and the concentration of TNF was higher in the monocytes of patients with MPNs than in those of controls.
They also found that patients with MPN and controls had a similar fraction of CD14-positive and CD16-positive proinflammatory monocytes, so increased TNF production could not be explained by an increased fraction of monocytes actively producing TNF.
Failure to dampen TLR signaling, they say, may be responsible for persistent TNF production, and a defect in the TLR signaling negative feedback loop—namely, a blunted response to interleukin 10 (IL-10)—may be the cause. The degree of resistance to IL-10, they write, correlates with TNF persistence in patients with MPNs.
Notably, the investigators obtained monocytes from a patient with PV and from an unaffected twin sibling. Both the patient and the twin had prolonged production of TNF and IL-10, and the monocytes of the unaffected twin were less able to dampen TNF production. This suggests that the abnormality predates the development of MPN and may actually predispose individuals to acquire an MPN.
The authors add that, in addition to the chronic inflammation observed that results from dampened IL-10 signaling, it is likely that prolonged TLR signaling could extend to other immune cell populations, such as hematopoietic stem cells, and further studies should examine this possibility.
Reference
Lai HY, Brooks SA, Craver BM, et al. Defective negative regulation of toll-like receptor signaling leads to excessive TNF-a in myeloproliferative neoplasm. Blood Adv. 2019;3(2):122-131. doi: 10.1182/bloodadvances.2018026450.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More